Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
Ryul Kim, Bhumsuk Keam, Sehui Kim et al. · BMC Cancer · 2019
We aimed to compare intra- and extracranial responses to immune checkpoint inhibitors (ICIs) in lung cancer with brain metastases (BM), and to explore tumor microenvironments of the brain and lungs focusing on the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway. Two cohorts of lung cancer patients with BM were analyzed. Cohort 1 included 18 patients treated with nivolumab or pembrolizumab, and intra- and extracranial responses were assessed. Cohort 2 comprised 20 patients who underwent both primary lung surgery and brain metastasectomy. Specimens from cohort 2 were subjected to immunohistochemical analysis for the following markers: CD3, CD4, CD8, FOXP3, and PD-1 on tumor infiltrating lymphocytes (TIL) and PD-L1 on tumor cells. Seven patients (38.9%) in cohort 1 showed progressive disease in both primary and intracranial lesions. Although the other 11 patients exhibited a partial response or stable disease in the primary lesion, eight showed a progression in BM. Interestingly, PD-1 + TILs were significantly decreased in BM ( P = 0.034). For fifteen patients with adenocarcinoma, more distinctive patterns were observed in CD3 + ( P = 0.078), CD8 + ( P = 0.055), FOXP3 + ( P = 0.016), and PD-1 + ( P = 0.016) TILs. There may be discordant responses to an ICI of lung cancer between primary lung lesion and BM based on discrepancies in the tumor microenvironment. The diminished infiltration of PD-1 + TILs in tumor tissue within the brain may be one of the major factors that hinder the response to anti–PD-1 antibody in BM.
Cited by 89 works. doi:10.1186/s12885-018-5214-8 Open-access PDF
Authors
- Ryul Kim
- Bhumsuk Keam
- Sehui Kim
- Miso Kim
- Se Hyun Kim
- Jin‐Wook Kim
- Yu Jung Kim
- Tae Min Kim
- Yoon Kyung Jeon
- Dong‐Wan Kim
- Doo Hyun Chung
- Jong Seok Lee
- Dae Seog Heo
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma